Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal Adenocarcinoma

PROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity.

Subsidie
€ 1.999.401
2023

Projectdetails

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is a life-threatening disease with few treatment options. Recently, the chemical space for targeted therapeutics was significantly increased by the development of compounds that induce protein degradation (PROTACs), but so far, they are unavailable for PDAC. The main motivation of PROTAC-PDAC is to develop novel targeted therapies for PDAC.

Project Background

The project is based on our accomplishments in three crucial areas:

  1. My group identified – as target candidates – a series of transcription factors that are absolutely required for PDAC growth in vivo.
  2. We developed dozens of potent, specific PROTACs, thereby gaining deep insight into the underlying design principles and synthesis procedures.
  3. We established genetic models in mice for simulating PROTAC function and discovering ideal target–E3 ligase pairs.

Project Goals

In PROTAC-PDAC, we will develop compounds that degrade key oncogenic transcription factors and inhibit pancreatic tumor growth with minimal toxicity in healthy tissues.

Aim I

We will start by implementing the Auxin degron system in a murine PDAC model to induce degradation of the target candidates and select four priority targets with the highest therapeutic index.

Aim II

Then, we will assess their oncogenic functions by analyzing molecular, cellular, and organismic consequences of acute depletion in mice.

Aim III

In parallel, we will develop pharmaceutical PROTACs to induce target degradation and analyze their efficacy in PDAC models.

Aim IV

Finally, with the aim of developing less toxic PDAC therapy, we will identify pancreatic E3 ligases for the design of the first tissue-specific PROTACs that induce target degradation primarily in pancreatic tumor cells.

Conclusion

While the main goal of PROTAC-PDAC is to develop new PROTAC-based therapeutic strategies, we will also establish groundbreaking methods and models leading to fundamental discoveries in PDAC biology.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.999.401
Totale projectbegroting€ 1.999.401

Tijdlijn

Startdatum1-12-2023
Einddatum30-11-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIELpenvoerder
  • JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860

Vergelijkbare projecten uit andere regelingen

ERC STG

Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approach

TrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space.

€ 1.499.625
ERC POC

Targeting bicarbonate transport as a “first-in-class” therapeutic strategy to promote CD8+ T cell fitness and enhance cancer immunotherapy

This project aims to develop and commercialize bicarbonate transporter blockers to enhance CD8+ T cell efficacy and improve immunotherapy outcomes in pancreatic cancer.

€ 150.000
ERC POC

Generating mRNA-HNF4a-Lipid nanoparticles for curing pancreatic cancer-associated cachexia (CAC) in identified patients at risk

This project aims to develop and test liver-specific mRNA therapies targeting HNF4a to prevent or alleviate cancer-associated cachexia in pancreatic cancer patients identified by a novel liver score.

€ 150.000
ERC POC

KRAS-AlphaTACs: a novel class of biotherapeutics to target KRAS

The project aims to develop and pre-clinically validate AlphaTACs for targeted degradation of KRAS proteins to advance cancer therapy and support a new spin-off company.

€ 150.000